The Obstructive Hypertrophic Cardiomyopathy Pipeline report embraces in-depth commercial and clinical assessment of the Obstructive Hypertrophic Cardiomyopathy pipeline products from the pre-clinical developmental phase to the marketed phase.
The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Obstructive Hypertrophic Cardiomyopathy collaborations, mergers, acquisition, funding, designations, and other product-related details.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/obstructive-hypertrophic-cardiomyopathy-hcm-pipeline-insight
Pharmacotherapy is the most frequently used therapy for HCM, mostly HOCM. The clinical intention is to manage symptoms related to left ventricle outflow tract obstruction. The mainstay of the therapy is a combination of three types of drugs: β-adrenergic antagonist, calcium channel blockers, and antiarrhythmic drugs. Besides these pharmacotherapies, the two mechanical therapies recommended to treat HOCM are surgical myomectomy and catheter-based alcohol septal ablation.
The pipeline of Hypertrophic Obstructive Cardiomyopathy (HOCM) is very narrow with few potential key players involved in the therapeutics development, which reflects that there is a high medical unmet need for potential treatment options for the patients.
The key companies in the Obstructive Hypertrophic Cardiomyopathy (HCM) market include –
-
MyoKardia
-
Cytokinetics
-
Belcher Pharmaceuticals
And many other
Obstructive Hypertrophic Cardiomyopathy Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Obstructive Hypertrophic Cardiomyopathy with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Obstructive Hypertrophic Cardiomyopathy Treatment.
-
Obstructive Hypertrophic Cardiomyopathy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Obstructive Hypertrophic Cardiomyopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obstructive Hypertrophic Cardiomyopathy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
The Obstructive Hypertrophic Cardiomyopathy (HCM) therapies covered in the report include –
-
Mavacamten – MyoKardia is developing Mavacamten for the treatment of HOCM. It is an orally administered, small molecule modulator of cardiac myosin, that targets underlying biomechanical abnormalities in HOCM.
-
CK-3773274 – CK-3773274 (CK-274) is being developed by Cytokinetics, which is a novel, oral, small molecule cardiac myosin inhibitor that was designed to reduce the hyper-contractility that is associated with hypertrophic cardiomyopathy (HCM). It reduces the number of active actin-myosin cross-bridges during each cardiac cycle and consequently reduces myocardial contractility.
The dynamics of the Hypertrophic Obstructive Cardiomyopathy market is anticipated to change in the coming years owing to the improvement in the research and development activities and the launch of the emerging therapies.
Report Highlights
-
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Obstructive Hypertrophic Cardiomyopathy.
-
In the coming years, the Obstructive Hypertrophic Cardiomyopathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
-
The companies and academics are working to assess challenges and seek opportunities that could influence Obstructive Hypertrophic Cardiomyopathy Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
-
A detailed portfolio of major pharma players who are involved in fueling the Obstructive Hypertrophic Cardiomyopathy treatment market. Several potential therapies for Obstructive Hypertrophic Cardiomyopathy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Obstructive Hypertrophic Cardiomyopathy market size in the coming years.
-
Our in-depth analysis of the Obstructive Hypertrophic Cardiomyopathy pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of Content
1. Report Introduction
2. Obstructive Hypertrophic Cardiomyopathy
3. Obstructive Hypertrophic Cardiomyopathy Current Treatment Patterns
4. Obstructive Hypertrophic Cardiomyopathy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Obstructive Hypertrophic Cardiomyopathy Late Stage Products (Phase-III)
7. Obstructive Hypertrophic Cardiomyopathy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Obstructive Hypertrophic Cardiomyopathy Discontinued Products
13. Obstructive Hypertrophic Cardiomyopathy Product Profiles
14. Obstructive Hypertrophic Cardiomyopathy Key Companies
15. Obstructive Hypertrophic Cardiomyopathy Key Products
16. Dormant and Discontinued Products
17. Obstructive Hypertrophic Cardiomyopathy Unmet Needs
18. Obstructive Hypertrophic Cardiomyopathy Future Perspectives
19. Obstructive Hypertrophic Cardiomyopathy Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/obstructive-hypertrophic-cardiomyopathy-hcm-pipeline-insight
Latest Reports By DelveInsight
Substance (Drug) Abuse Market
DelveInsight’s “Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Substance (Drug) Abusemarket size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
US Healthcare Market Outlook
DelveInsight’s, “US Healthcare Outlook Report, 2020,” report provides comprehensive insights about healthcare scenarios, regulatory policies, and reimbursement landscape in the US. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of the US.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/